The completion of the full BLA submission is anticipated in early 2026 and is eligible for priority review under the program’s fast-track designation.

Talcott’s presentation focused on phase 2 clinical trial results of a therapeutic in development: EYP-1901, which aims to reduce treatment burden for wet AMD. This candidate is a bioerodible, ...

Belite Bio completes enrollment in the pivotal PHOENIX trial, advancing Tinlarebant's potential to treat geographic atrophy.

Boehringer Ingelheim initiates THULITE study, exploring an oral treatment for diabetic macular edema, aimed to improve patient care and convenience.

Atsena Therapeutics expands its ATSN-201 trial for X-linked retinoschisis, a step toward the first gene therapy treatment.

The VISTA trial is evaluating and comparing 2 dose levels of laru-zova to an untreated control group for the treatment of X-linked retinitis pigmentosa (XLRP).

Clinical research sites face challenges in managing the growing complexity of trials. The increasing administrative burden, protocol complexities, constant staff turnover, and operational ...

At the 2025 Annual Meeting, I had the privilege of 1 I have been working on over the past year—exploring how retinal imaging might help detect early signs of Alzheimer disease (AD), especially in ...

In May 2025, Dilsher S. Dhoot, MD, moderated a Case-Based Roundtable® that brought together practicing retina specialists and residents from the Bascom Palmer Eye Institute’s residency program. The ...

As a medical student, I have had the opportunity to join the iMIND lab at Duke University and contribute to the growing and captivating neuro-ophthalmology field, which expands our understanding of ...

The diabetic macular edema section is a comprehensive resource for Ophthalmology news and expert insights. Read more at Modern Retina.

July 6th 2025 New clinical trials reveal PER-001 as a new treatment for glaucoma and diabetic retinopathy, showing significant vision improvements and safety.